中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
10期
95-97
,共3页
齐拉西酮%利培酮%精神分裂症%认知功能
齊拉西酮%利培酮%精神分裂癥%認知功能
제랍서동%리배동%정신분렬증%인지공능
Ziprasidone%Risperidone%Schizophrenia%Cognitive function
目的 探讨齐拉西酮与利培酮对首发分裂症的疗效和安全性,以及对认知功能影响.方法 将符合中国精神疾病分类方案与诊断标准第3版(CCMD-3)分裂症诊断标准的86例首发患者随机分为齐拉西酮组(n=42)和利培酮组(n=44),分别治疗观察8周.于治疗前和治疗2、4、6、8周末,用阳性症状及阴性症状量表(PANSS)和不良反应量表(TESS)评定疗效和副反应.用韦氏成人智力量表(WAIS-R)、韦氏记忆量表(WMS)和威斯康星卡片分类测验(WCST)于治疗前后进行认知功能评定.结果 两组PANSS总分治疗前后均有显著性差异(P<0.01),齐拉西酮组有效率92.5%,显效率80%;利培酮组有效率90%,显效率80%,两组疗效无显著性差异(P>0.05).治疗6、8周末TESS评分,齐拉西酮组均低于利培酮组,两组有显著性差异(P<0.01).两组WAIS-R言语量表、操作量表、全量表和WMS记忆商数及WCST总测验数、持续错误数和随机错误数治疗前后均有显著性差异(P<0.05或P<0.01),治疗后两组WMS记忆商数和WCST持续错误数有显著性差异(P<0.05).结论 齐拉西酮是一种安全有效的非典型抗精神病药物,临床疗效与利培酮相当,并且具有副作用少而轻以及对认知功能的改善明显优于利培酮的特点,可作为治疗精神分裂症的首选药物.
目的 探討齊拉西酮與利培酮對首髮分裂癥的療效和安全性,以及對認知功能影響.方法 將符閤中國精神疾病分類方案與診斷標準第3版(CCMD-3)分裂癥診斷標準的86例首髮患者隨機分為齊拉西酮組(n=42)和利培酮組(n=44),分彆治療觀察8週.于治療前和治療2、4、6、8週末,用暘性癥狀及陰性癥狀量錶(PANSS)和不良反應量錶(TESS)評定療效和副反應.用韋氏成人智力量錶(WAIS-R)、韋氏記憶量錶(WMS)和威斯康星卡片分類測驗(WCST)于治療前後進行認知功能評定.結果 兩組PANSS總分治療前後均有顯著性差異(P<0.01),齊拉西酮組有效率92.5%,顯效率80%;利培酮組有效率90%,顯效率80%,兩組療效無顯著性差異(P>0.05).治療6、8週末TESS評分,齊拉西酮組均低于利培酮組,兩組有顯著性差異(P<0.01).兩組WAIS-R言語量錶、操作量錶、全量錶和WMS記憶商數及WCST總測驗數、持續錯誤數和隨機錯誤數治療前後均有顯著性差異(P<0.05或P<0.01),治療後兩組WMS記憶商數和WCST持續錯誤數有顯著性差異(P<0.05).結論 齊拉西酮是一種安全有效的非典型抗精神病藥物,臨床療效與利培酮相噹,併且具有副作用少而輕以及對認知功能的改善明顯優于利培酮的特點,可作為治療精神分裂癥的首選藥物.
목적 탐토제랍서동여리배동대수발분렬증적료효화안전성,이급대인지공능영향.방법 장부합중국정신질병분류방안여진단표준제3판(CCMD-3)분렬증진단표준적86례수발환자수궤분위제랍서동조(n=42)화리배동조(n=44),분별치료관찰8주.우치료전화치료2、4、6、8주말,용양성증상급음성증상량표(PANSS)화불량반응량표(TESS)평정료효화부반응.용위씨성인지역량표(WAIS-R)、위씨기억량표(WMS)화위사강성잡편분류측험(WCST)우치료전후진행인지공능평정.결과 량조PANSS총분치료전후균유현저성차이(P<0.01),제랍서동조유효솔92.5%,현효솔80%;리배동조유효솔90%,현효솔80%,량조료효무현저성차이(P>0.05).치료6、8주말TESS평분,제랍서동조균저우리배동조,량조유현저성차이(P<0.01).량조WAIS-R언어량표、조작량표、전량표화WMS기억상수급WCST총측험수、지속착오수화수궤착오수치료전후균유현저성차이(P<0.05혹P<0.01),치료후량조WMS기억상수화WCST지속착오수유현저성차이(P<0.05).결론 제랍서동시일충안전유효적비전형항정신병약물,림상료효여리배동상당,병차구유부작용소이경이급대인지공능적개선명현우우리배동적특점,가작위치료정신분렬증적수선약물.
Objective To compare the effect of ziprasidone and risperidone on the efficacy and cognitive function in first-episode schizophrenia.Methods 86 first-episode inpatients who met CCMD-3 diagnostic criteria for schizophrenia were randomly divided into study group(n = 42) and control group(n=44) for an 8-week observation.The study group received ziprasidone,while the control group was treated with risperidone.The Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Symptoms Scale(TESS) were used to evaluate the efficacy and side effects respectively before and after 2,4,6,8 week's treatment.WAIS-R,WMS,WCST were adopted to evaluate the cognitive function before and after treatment.Results There were significant difference in the total scores of PANSS of the two group after treatment than before(P<0.01).The effective rate of ziprasidone group was 92.5%,in which 80% were improved remarkably.The effective rate of risperidone group was 90%,in which 80% were improved remarkably.There were significant difference in curative effect between the two groups(P>0.05).The scores of TESS of study group were significantly lower than those of control group at 6,8 weekend(P<0.01).The scores of WAIS-R language scale,operation scale,total scale,memory quotient(MQ),total trials,persistent errors and random errors of W CST were improved significantly in two group compared with before treatment(P < 0.05 or P < 0.01).After the treatment,there was remarkable difference on the scores of MQ and persistent errors in study group compared with those in control group(P<0.05).Conclusion Ziprasidone is a safe and effective atypical antipsychotics,and it's curative effect is similar to risperidone.However,ziprasidone has few and slight side effects as well as the improvement of the cognitive function of first-episode schizophrenia obviously,it can be used as choice drug for first-episode schizophrenia.